Elan to restart MS drug trials

IRISH brokers reacted positively to the partial lifting of restrictions on Elan and Biogen's multiple sclerosis drug, Tysabri.

This followed the decision by the US Food and Drug Administration (FDA) to allow trials of the drug to restart.

NCB and Goodbody put a buy on the stock yesterday following the announcement on Wednesday that clinical trial dosing can resume on patients who took part in the Phase III tests.